Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other financing activities (2019 - 2023)

Historic Other financing activities for Summit Therapeutics (SMMT) over the last 5 years, with Q2 2023 value amounting to $80000.0.

  • Summit Therapeutics' Other financing activities changed N/A to $80000.0 in Q2 2023 from the same period last year, while for Mar 2024 it was $80000.0, marking a year-over-year decrease of 8769.23%. This contributed to the annual value of $619000.0 for FY2023, which is 45765.77% up from last year.
  • Summit Therapeutics' Other financing activities amounted to $80000.0 in Q2 2023.
  • Summit Therapeutics' Other financing activities' 5-year high stood at $539000.0 during Q1 2023, with a 5-year trough of -$41000.0 in Q4 2021.
  • Its 5-year average for Other financing activities is $160571.4, with a median of $80000.0 in 2023.
  • Per our database at Business Quant, Summit Therapeutics' Other financing activities plummeted by 18541.67% in 2021 and then surged by 10555.56% in 2022.
  • Over the past 5 years, Summit Therapeutics' Other financing activities (Quarter) stood at $333000.0 in 2019, then crashed by 85.59% to $48000.0 in 2020, then crashed by 185.42% to -$41000.0 in 2021, then skyrocketed by 370.73% to $111000.0 in 2022, then fell by 27.93% to $80000.0 in 2023.
  • Its Other financing activities stands at $80000.0 for Q2 2023, versus $539000.0 for Q1 2023 and $111000.0 for Q3 2022.